Rare
lephants
Screener
Toggle theme
I
Interpace Biosciences, Inc.
IDXGD
·
Healthcare, Medical Devices, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2011
FY2010
Total Cash from Operations:
$7.3M
Line Item
Value
% of Total
Capital Expenditures
$609.0K
8.4%
Other Financing
$4.0M
55.4%
Working Capital
$2.6M
36.3%
Net Cash Flow
$0
0.0%
Download CSV